AFP-L3 Detection via Lectin-Coupled Magnetic Particles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting alpha-fetoprotein variants, particularly AFP-L3, are cumbersome, time-consuming, and lack automation, leading to low sensitivity and high variability in results, making it difficult to distinguish between benign and malignant liver conditions and hindering early detection of hepatocellular carcinoma.
Innovation Solution
A card and system utilizing epoxy resin-coated magnetic particles coupled with lectin for specific binding of AFP-L3, combined with anti-alpha-fetoprotein antibodies and enzyme-labeled antibodies for detection, enabling rapid and accurate separation and quantification of AFP-L3 in a sample, with a magnetic separation module and chemiluminescence detection for high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If manual separation and detection methods are used for AFP-L3, then detection can be performed, but the process is cumbersome, time-consuming, and lacks automation
Solution Approach 1:
The magnetic particles automatically separate and concentrate AFP-L3 through magnetic field action without requiring manual intervention. The system performs self-service separation where the magnetic particles bind to AFP-L3 and are automatically drawn to the magnetic separation area, eliminating the need for manual centrifugation or filtration steps.
Solution Approach 2:
The patent replaces manual mechanical separation operations with a magnetic field-based automated system. Instead of manual centrifugation or filtration, magnetic particles coupled with lectin are used to bind AFP-L3 and are separated through magnetic field application, enabling automated detection within 30 minutes.
2Measurement precision
If manual separation methods are used for AFP-L3, then detection is possible, but sensitivity is low and results show high variability
Solution Approach 1:
The patent applies local quality by coupling lectin specifically to magnetic particles, creating a localized binding site that selectively targets AFP-L3. This localized functionalization enhances detection sensitivity and specificity while maintaining system simplicity, as only the magnetic particles require special modification rather than the entire system.
Solution Approach 2:
The patent changes the physical state and properties of the detection system by introducing magnetic particles that can be easily manipulated through magnetic field application. This parameter change enables rapid separation and concentration of AFP-L3, improving detection sensitivity and result consistency without significantly increasing system complexity.
3Reliability
If AFP detection is used for liver cancer screening, then early detection is attempted, but it cannot distinguish between benign liver disease and malignant tumors
Solution Approach 1:
The patent extracts and specifically detects the AFP-L3 variant from total AFP using lectin-coupled magnetic particles. By isolating and measuring the AFP-L3 fraction separately, the system provides diagnostic information that distinguishes malignant liver tumors from benign liver diseases, improving diagnostic accuracy while maintaining screening efficiency.
Solution Approach 2:
The patent uses lectin as an intermediary substance that specifically binds to AFP-L3. This intermediary enables selective detection of the malignant marker variant without interfering with the detection of total AFP, allowing simultaneous assessment of both overall AFP levels and the specific AFP-L3 fraction for improved diagnostic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for quick and accurate detection of AFP-L3 within 30 minutes, achieving high sensitivity and specificity, supporting early diagnosis and treatment of hepatocellular carcinoma with improved automation and reduced manual errors.
Implementation Method 1
magnetic particles coupling a lectin are used to specifically bind to AFP-L3 in the sample to be detected
Implementation Method 2
epoxy resin coated magnetic particles coupling a lectin
Implementation Method 3
enzyme-labeled anti-alpha-fetoprotein antibody, and wherein the card comprises a sample well, a reagent tank containing the magnetic particles coupling a lectin, a reagent tank containing the eluent, a reagent tank containing the magnetic particles coated with an anti-alpha-fetoprotein antibody, a reagent tank containing an enzyme-labelled anti-alpha-fetoprotein antibody
Data Source
Figure 1~2
Figure 3
AI summary
Disclosed are a composition and system for separating and detecting an alpha-fetoprotein variant, comprising a separation reagent and a detection reagent; a system for separating and detecting an alpha-fetoprotein variant and a use thereof; and a kit for separating and detecting the alpha-fetoprotein variant. By means of the composition and system for separating and detecting the alpha-fetoprotein variant, and the use thereof, primary liver cancer can be indicated early on, the sensitivity is high, and the method is rapid, simple and automated.